The global molecular point of care testing (using NAAT) market size was valued at USD 37.93 billion in 2024 and is expected to reach USD 86.17 billion by 2032, at a CAGR of 1.08% during the forecast period

This market growth is primarily driven by the increasing prevalence of infectious diseases, the demand for rapid and accurate diagnostic testing, and advancements in molecular diagnostic technologies

In addition, the shift towards decentralized healthcare and the growing adoption of multiplex tests are contributing to the expansion of the molecular POCT market. These factors collectively position molecular point-of-care testing as a pivotal component in modern diagnostics, offering timely and precise detection of various health conditions